Brookstone Capital Management lifted its stake in Becton, Dickinson and Company (NYSE: BDX – Get Rating) by 124.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,397 shares of the medical instruments supplier’s stock after acquiring an additional 2,435 shares during the quarter. Brookstone Capital Management’s holdings in Becton, Dickinson and were worth $ 1,187,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of BDX. Norges Bank acquired a new position in shares of Becton, Dickinson and in the 4th quarter worth approximately $ 663,055,000. Diamond Hill Capital Management Inc. acquired a new position in shares of Becton, Dickinson and in the 4th quarter worth approximately $ 395,149,000. BlackRock Inc. lifted its holdings in shares of Becton, Dickinson and by 4.2% in the 4th quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock worth $ 5,204,300,000 after acquiring an additional 828,789 shares during the last quarter. Invesco Ltd. increased its stake in Becton, Dickinson and by 19.6% during the 4th quarter. Invesco Ltd. now owns 3,075,333 shares of the medical instruments supplier’s stock worth $ 773,385,000 after buying an additional 504,932 shares during the period. Finally, State Street Corp increased its stake in Becton, Dickinson and by 3.9% during the 4th quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock worth $ 3,195,105,000 after buying an additional 480,684 shares during the period. Hedge funds and other institutional investors own 86.58% of the company stock.
Several equities research analysts recently weighed in on BDX shares. Morgan Stanley upped their target price on shares of Becton, Dickinson and from $ 293.00 to $ 295.00 and gave the stock an “overweight” rating in a research note on Monday, April 11th. Piper Sandler cut their target price on shares of Becton, Dickinson and from $ 265.00 to $ 255.00 in a research note on Thursday, May 5th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Friday. Argus upped their target price on shares of Becton, Dickinson and from $ 275.00 to $ 310.00 in a research note on Monday, February 28th. Finally, Bank of America assumed coverage on shares of Becton, Dickinson and in a research report on Tuesday, March 1st. They issued a “neutral” rating on the stock. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $ 279.17.
Shares of NYSE: BDX opened at $ 250.92 on Friday. Becton, Dickinson and Company has a 52 week low of $ 231.46 and a 52 week high of $ 280.62. The company 50 day moving average is $ 251.17 and its two-hundred day moving average is $ 258.18. The company has a current ratio of 1.52, a quick ratio of 1.04 and a debt-to-equity ratio of 0.72. The company has a market cap of $ 71.53 billion, a PE ratio of 39.58, a P / E / G ratio of 3.21 and a beta of 0.64.
Becton, Dickinson and (NYSE: BDX – Get Rating) last issued its earnings results on Thursday, May 5th. The medical instruments supplier reported $ 3.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $ 2.98 by $ 0.20. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The business had revenue of $ 5.01 billion during the quarter, compared to analysts’ expectations of $ 4.78 billion. During the same quarter in the prior year, the business posted $ 3.19 EPS. The company revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities research analysts expect that Becton, Dickinson and Company will post 11.2 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be issued a $ 0.87 dividend. This represents a $ 3.48 annualized dividend and a dividend yield of 1.39%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and his payout ratio is 54.89%.
In related news, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $ 260.00, for a total transaction of $ 115,180.00. Following the completion of the sale, the vice president now owns 1,058 shares in the company, valued at approximately $ 275,080. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Hickey sold 475 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $ 256.00, for a total transaction of $ 121,600.00. Following the sale, the executive vice president now owns 3,806 shares of the company stock, valued at approximately $ 974,336. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company stock.
Becton, Dickinson and Company Profile: (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and and related companies with MarketBeat.com’s FREE daily email newsletter.